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A 68-year-old woman presented with a visual field defect in her right eye. The fundus of her right eye showed multi-
ple telangiectatic vessels, retinal hemorrhages, and subretinal exudates in the inferior peripheral retina. Nine 
months later, the subretinal exudates extended to the fovea despite treatment with laser photocoagulation. 
Cryotherapy was not possible at the time because of the posterior location of the retinal telangiectatic vessels. She 
was treated with a combination of photodynamic therapy (PDT) and intravitreal bevacizumab injection: three in-
jections were given at 2-month intervals. After this combined therapy, her right fundus revealed a significant re-
gression of abnormal retinal vessels and subretinal exudates. A fluorescein angiography showed no leakage from 
the abnormal retinal vessels. At 9 months after the combined therapy, she was able to maintain a stable visual acuity 
and visual field. This is the first case report that demonstrates the efficacy of the combined treatment of PDT and in-
travitreal bevacizumab injection in Coats's disease. This combined therapy is a kind of treatment modality for adult 
Coats’ disease in cases which cryotherapy cannot be employed and are refractory to laser photocoagulation.
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Coats' disease is an idiopathic condition characterized by 
telangiectatic and aneurysmal retinal vessels and chronic 
accumulation of subretinal exudates [1]. It is predominantly 
unilateral occurring mostly in young males, and can cause se-
vere visual loss resulting from exudative retinal detachment 
[2]. Less commonly, it presents in adulthood and progresses 
at a slower rate, but with similar features [3].
Current treatment options for patients with Coat's disease 
are ablation of abnormal retinal vessels, either by laser pho-
tocoagulation or by cryotherapy, and surgery for retinal 
detachment. Recently, the dysregulation of vascular endothe-
lial growth factor (VEGF)-mediated angiogenesis was sug-
gested to be a component in Coats' disease and a few pedia-
tric patients with the disease have been reported to respond 
well to anti-VEGF therapy [4,5]. However, the involvement 
of the macula as a result of subretinal exudates or exudative 
retinal detachment can produce poor visual acuity despite 
proper treatment [2].
 In this article, we report the first case of 
an adult patient with macula-threatening Coats' disease, 
treated with a combined treatment of photodynamic therapy 
(PDT) and intravitreal bevacizumab injection.
Case Report
A 68-year-old woman presented with symptoms of a con-
stricted visual field in her right eye. Although the best-cor-
rected visual acuity (BCVA) was 20/25 in both eyes, a fundus 
examination revealed multiple telangiectatic and aneurysmal 
retinal vessels, retinal hemorrhages, and subretinal exudates 
at the inferior mid-periphery of her right eye. A fluorescein 
angiography showed early and persistent leakage in the ab-
normal vessels at the inferior mid-periphery and hypofluor-
escence corresponding to the subretinal exudates in the right 
eye. With the diagnosis of adult Coats' disease, scatter laser 
photocoagulation was applied to the abnormal retinal vessels.
At 9 months after presentation, a fundus examination re-
vealed about 1 disc diameter extension of the subretinal exu-





Fig. 1. Serial montage fundus photographs (left) and fluorescein angiographs (middle and right) of the right eye. (A) Two days before photo-
dynamic therapy (PDT). The subretinal exudates were threatening the fovea. Dotted circles indicate PDT treatment areas. Fluorescein angiog-
raphy reveals dye leakage from the abnormal retinal vessels and hypofluorescence corresponding to the subretinal exudates. (B) Six months 
post-PDT, significant regression of the abnormal retinal vessels and subretinal exudates was observed. (C) Nine months post-PDT, the sub-
retinal exudates shrank to become more distant from the fovea.
areas of abnormal telangiectatic and aneurysmal retinal ves-
sels (Fig. 1A). After the PDT treatment, intravitreal bevacizumab 
was injected in order to decrease exudation and to block the 
regeneration of abnormal retinal vessels which were obli-
terated by PDT. 
At 2 months post-PDT, a second intravitreal bevacizumab 
injection was given. At 4 months post-PDT, a third intra-
vitreal bevacizumab injection was given and an additional 
scatter laser photocoagulation was applied to the area where 
the pre-existing abnormal retinal vessels and subretinal exu-
dates had been located. At 6 months post-PDT, a fundus ex-
amination of the right eye showed a significant regression of 
the abnormal retinal vessels and subretinal exudates (Fig. 
1B). At 9 months post-PDT, the subretinal exudates with-
drew further from the fovea and the patient’s visual acuity re-
mained stable with a BCVA of 20/25 in both eyes (Figs. 1C 
and 2).
Discussion
The conventional treatment for Coats' disease involves la-
ser photocoagulation or cryotherapy to ablate abnormal te-
langiectatic vessels and preserve visual acuity. The sub-
retinal exudates regress after laser photocoagulation or 
cryotherapy. However, in our case the high intensity laser 
photocoagulation applied to the abnormal retinal vessels was 
not absorbed sufficiently, due to the massive retinal exudates.
We thought that PDT would be more effective than laser 
photocoagulation at obliterating the multiple abnormal reti-
nal vessels that were surrounded by the massive retinal 
exudates. Laser photocoagulation is not an efficient treat-
ment modality if subretinal exudates obscure a target tissue. Korean J Ophthalmol Vol.24, No.6, 2010
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Fig. 2. Sequential changes in the distance between subretinal exu-
dates and the fovea before and after photodynamic therapy (PDT). 
After PDT, the lesion-to-fovea distance increased gradually. 
DD=disc diameter.
However, PDT utilizes an exogenous agent, photosensitizing 
the abnormal retinal vessels that are surrounded by exudates 
and the interaction between the laser beam and the agent pro-
duces a photochemical reaction that results in cellular damage 
and vascular thrombosis of target tissue [6].
We considered that an additional use of anti-VEGF agent 
could prevent the regeneration of abnormal retinal vessels 
that were obliterated by PDT and could suppress exudation 
induced by inflammatory cytokines. Abnormal retinal ves-
sels and exudates in Coats' disease may impair the oxygen-
ation of the outer retina, and the secondary over-expression 
of VEGF that gets produced as a result may cause micro-
vascular changes [4].
  This mechanism suggests that an-
ti-VEGF is a potentially good treatment modality for Coats' 
disease, which was evident in case reports [4,5]. In addition, 
anti-VEGF had a synergistic effect on PDT for the treatment 
of choroidal neovascularization. Costa et al. [7] suggested 
that anti-VEGF might prolong choriocapillaris hypo-
perfusion induced by PDT, thus leading to a secondary effect 
on perfusion of choroidal neovascularization.
We are unable to comment on the potential long-term ef-
fect of the combined treatment of PDT and intravitreal 
bevacizumab injection, based on this single case. Further re-
search is needed to determine the efficacy of this combined 
therapy for the treatment of Coats' disease. However, we are 
optimistic about the role of this combined treatment in cases 
of Coats' disease that are refractory to conventional laser 
photocoagulation or cryotherapy-based treatment, and in vi-
sion-threatening conditions needing urgent treatment. 
In conclusion, combined treatment of PDT and intravitreal 
bevacizumab injection is a kind of treatment modality for 
cases of adult Coats' disease which cannot be treated by cry-
otherapy and are refractory to laser photocoagulation.
Conflict of Interest
No potential conflict of interest relevant to this article was 
reported.
References
  1. Coats G. Forms of retinal diseases with massive exudation. Roy 
Lond Ophthalmol Hosp Rep 1908;17:440-525.
    2. Shields JA, Shields CL, Honavar SG, Demirci H. Clinical 
variations and complications of Coats disease in 150 cases: the 
2000 Sanford Gifford Memorial Lecture. Am J Ophthalmol 
2001;131:561-71.
  3. Smithen LM, Brown GC, Brucker AJ, et al. Coats' disease 
diagnosed in adulthood. Ophthalmology 2005;112:1072-8.
  4. Sun Y, Jain A, Moshfeghi DM. Elevated vascular endothelial 
growth factor levels in Coats disease: rapid response to pega-
ptanib sodium. Graefes  Arch Clin Exp Ophthalmol 2007;245: 
1387-8.
  5. Cakir M, Cekiç O, Yilmaz OF. Combined intravitreal bevaciz-
umab and triamcinolone injection in a child with Coats disease. 
J AAPOS 2008;12:309-11.
  6. Miller JW, Walsh AW, Kramer M, et al. Photodynamic therapy 
of experimental choroidal neovascularization using lipoprotein- 
delivered benzoporphyrin. Arch Ophthalmol 1995;113:810-8. 
  7. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab 
(Avastin) in combination with verteporfin photodynamic 
therapy for choroidal neovascularization associated with 
age-related macular degeneration (IBeVe Study). Graefes Arch 
Clin Exp Ophthalmol 2007;245:1273-80.